Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05100342 · ClinicalTrials.gov registry record
Prospective Validation of a Points Score System Predicting 30-day Survival
A clinical trial of Metastatic Cancer, sponsored by Indiana University.
- Recruiting
- Registry status
- 114
- Enrollment target
- 3
- Study locations
NCT05100342 is a study of Metastatic Cancer that is actively recruiting participants, run by Indiana University. The registered enrollment target is 114 participants, below the 443-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (74% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT05100342, a study of Metastatic Cancer, is actively recruiting participants, sponsored by Indiana University.
- RECRUITING
- Registry status
- 114 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a one-stage single-arm phase II clinical trial designed to prospectively test the survival prediction tool as developed by Lee et al on patients referred to radiation oncology for palliative treatments. Survival prediction score based on objective data including laboratory values, attendance to emergency room, and primary cancer origin will be assigned to each patient at time of enrollment.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Point score prediction tool for 30-day survival
Study Locations (3)
Indiana
- IU Health West - Avon
- IU Health North / Schwarz Cancer Center - Carmel
- Methodist Hospital - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2022-09-12 |
| Est. Completion | 2027-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05100342
The ClinicalTrials.gov registry entry for NCT05100342 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 443-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (74% lower). The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Point score prediction tool for 30-day survival is the first listed.
NCT05100342 reports 3 study locations spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT05100342 about?
NCT05100342 is a clinical study titled "Prospective Validation of a Points Score System Predicting 30-day Survival". This is a one-stage single-arm phase II clinical trial designed to prospectively test the survival prediction tool as developed by Lee et al on patients referred to radiation oncology for palliative treatments. Survival prediction score based on objective data including laboratory values, attendance...
What is the current status of trial NCT05100342?
This trial is currently recruiting. The enrollment target is 114 participants. The study started on 2022-09-12. Estimated completion is 2027-12.
What conditions does trial NCT05100342 study?
This clinical trial studies the following conditions: Metastatic Cancer.
What interventions are being tested in trial NCT05100342?
The interventions under investigation include: Point score prediction tool for 30-day survival (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05100342?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05100342 being conducted?
This trial has 3 study locations across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating Disparities in Precision Oncology
RECRUITING
-
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
RECRUITING · Phase 1
-
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
RECRUITING · Phase 2
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.